TREATMENT METHOD AND DEVICE FOR IMPROVED BIOAVAILABILITY OF MONTELUKAST, A LEUKOTRIE RECEPTOR ANTAGONIST

DE602019085466T2Active Publication Date: 2026-06-03NUALTIS CORP ST-LAURENT
0 Cites 0 Cited by

Patent Information

Application Number
DE602019085466
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-09-14
Filing Date
2019-09-12
Publication Date
2026-06-03
Estimated Expiration
2039-09-12

AI Technical Summary

Technical Problem

Montelukast sodium, a leukotriene receptor antagonist, has inconsistent bioavailability due to reduced solubility in acidic stomach conditions, leading to slow and inconsistent absorption, limiting its effectiveness in treating neuroinflammatory disorders and neurodegenerative diseases.

Method used

An oral film dosage form with an alkaline surface pH greater than 7.5, containing Montelukast, which rapidly dissolves and disintegrates in the oral cavity, transforming into a precipitate for improved absorption across the blood-brain barrier.

Benefits of technology

Enhances bioavailability of Montelukast, allowing effective delivery to the brain for treating neuroinflammatory disorders and neurodegenerative diseases, with improved plasma and cerebrospinal fluid concentration levels.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.